Nektar pulls NDA for pain drug after unanimous AdComm rejection

Nektar Therapeutics has withdrawn the new drug application for its opioid oxycodegol after an advisory committee unanimously recommended against approval. The 27-0 vote against approval followed questioning of Nektar’s decision to run one pivotal trial and the extent to which it assessed the risk of abuse.